Filing Flows › Health Care › Starling Oncology (STLN)
Starling Oncology (STLN) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 6, 2026 · Starling Oncology (STLN) Q3 2026 earnings results →
Q3 2026 Revenue up 24% year over year to $170M · 9¢ of every $1 of revenue lost · operating margin -1.8%
Starling Oncology made $170M in Q3 2026 (+24% Y/Y): Specialty Pharmacy $109M, Patient services $60.0M. Operating margin -1.8%, net loss $15.7M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 6, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $169.8M in Q3 2026, up 24% year over year and up 5% from the previous quarter. Specialty Pharmacy was the largest line at 64% of revenue. Specialty Pharmacy added $33.4M year over year (up 44%), 101% of the total change. FFS revenue declined 21%.
Operating costs exceeded revenue by $3.0M, an operating margin of -1.8%. Total costs grew 19% against revenue growth of 24%. The fastest-growing cost line was SG&A (+27%). The quarter ended with a net loss of $15.7M, wider than the previous quarter's $9.8M loss. Net interest and other expense of $12.8M was the main reason.
Operating cash flow was $10.1M. Non-cash charges added back $1.5M of depreciation and amortization and $1.3M of share-based compensation. Working capital and other items added $23.0M. Capital expenditures of $1.3M left free cash flow of $8.9M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 6, 2026 | $170M | +24% | -1.8% | −$15.7M | $10.1M |
| Q2 2026 | 10-Q | Aug 6, 2026 | $161M | +35% | -2.9% | −$9.8M | $11.9M |
| Q1 2026 | 10-Q | May 7, 2026 | $147M | +41% | -4.4% | −$2.5M | −$2.2M |
| Q4 2025 | 10-K | Mar 12, 2026 | $142M | +42% | -4.9% | −$7.5M | $3.2M |
| Q3 2025 | 10-Q | Nov 13, 2025 | $137M | +37% | -5.9% | −$16.5M | −$12.6M |
| Q2 2025 | 10-Q | Aug 13, 2025 | $120M | +22% | -9.4% | −$17.0M | −$10.2M |
| Q1 2025 | 10-Q | May 14, 2025 | $104M | +10% | -9.5% | −$19.6M | −$5.0M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Sells to
- Medicare & Medicaid — 14% of its revenue · Stated in 10-K (sentence) · source
About Starling Oncology
Formed in 2007, the business of what is now The Oncology Institute, Inc. ("TOI", the "Company", "we", or "our) and its affiliated professional corporations was created initially as a collection of community oncology practices in southern California, and has evolved to be a national leader in the pursuit of reducing the ever-rising cost of oncology care, while embracing clinical best practices, state-of-the-art technology, and compassionate treatment of patients.
In its own words, from its 10-K, filed Mar 12, 2026.
Starling Oncology against its Services-Offices & Clinics of Doctors of Medicine peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +24% against the peers' median -3%. Operating margin: -1.8% against the peers' median -12.9%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| STLN Starling Oncology | Q3 2026 | $170M | +24% | -1.8% |
| HIMS Hims & Hers Health | Q2 2026 | $753M | +38% | -12.9% |
| TDOC Teladoc Health | Q3 2026 | $605M | -3% | -4.6% |
| SBC SBC Medical Group Holdings | Q2 2026 | $49.2M | +13% | 38.5% |
| LFMD LifeMD | Q2 2026 | $47.3M | -4% | -15.1% |
| AIRS Airsculpt Technologies | Q3 2026 | $31.9M | -9% | -13.0% |
| CDIX Cardiff Lexington | Q2 2026 | $2.2M | -23% | -25.2% |
| HLYK HealthLynked | Q2 2026 | $250K | -58% | -215.7% |
Source: Starling Oncology 10-Q on SEC EDGAR · CIK 1799191 · Services-Offices & Clinics of Doctors of Medicine
Guidance and outlook
13F: who owns STLN and who is buying
More on STLN
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results